Financhill
Sell
27

ABSI Quote, Financials, Valuation and Earnings

Last price:
$2.71
Seasonality move :
8.53%
Day range:
$2.62 - $2.80
52-week range:
$2.01 - $6.33
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
65.81x
P/B ratio:
1.75x
Volume:
2.2M
Avg. volume:
2.7M
1-year change:
-35.39%
Market cap:
$347M
Revenue:
$4.5M
EPS (TTM):
-$0.92

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ABSI
Absci
$1.3M -$0.22 9.25% -5.85% $9.13
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
RXRX
Recursion Pharmaceuticals
$18.1M -$0.52 12.7% -11% $7.43
TOVX
Theriva Biologics
-- -$1.56 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ABSI
Absci
$2.72 $9.13 $347M -- $0.00 0% 65.81x
NBY
NovaBay Pharmaceuticals
$0.57 $0.85 $3.3M -- $0.00 0% 0.16x
NNVC
Nanoviricides
$1.71 -- $27.5M -- $0.00 0% --
OGEN
Oragenics
$0.19 $1.00 $4.1M -- $0.00 0% 1.84x
RXRX
Recursion Pharmaceuticals
$4.39 $7.43 $1.8B -- $0.00 0% 23.19x
TOVX
Theriva Biologics
$0.43 $7.00 $3.5M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ABSI
Absci
1.6% 0.719 1.01% 4.96x
NBY
NovaBay Pharmaceuticals
4.54% -0.186 1.51% 0.75x
NNVC
Nanoviricides
-- 2.080 -- --
OGEN
Oragenics
-- 3.254 -- --
RXRX
Recursion Pharmaceuticals
2.61% 2.048 1.17% 3.85x
TOVX
Theriva Biologics
-- -2.512 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ABSI
Absci
-- -$27.7M -50.37% -51.63% -2228.24% -$21.9M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
NNVC
Nanoviricides
-- -$2.2M -- -- -- -$2M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
RXRX
Recursion Pharmaceuticals
-$7M -$191.4M -80% -82.61% -1364.13% -$133.8M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

Absci vs. Competitors

  • Which has Higher Returns ABSI or NBY?

    NovaBay Pharmaceuticals has a net margin of -2234.61% compared to Absci's net margin of -49.65%. Absci's return on equity of -51.63% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    ABSI
    Absci
    -- -$0.21 $202M
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About ABSI or NBY?

    Absci has a consensus price target of $9.13, signalling upside risk potential of 235.48%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 50.23%. Given that Absci has higher upside potential than NovaBay Pharmaceuticals, analysts believe Absci is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ABSI
    Absci
    5 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is ABSI or NBY More Risky?

    Absci has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

  • Which is a Better Dividend Stock ABSI or NBY?

    Absci has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ABSI or NBY?

    Absci quarterly revenues are $1.2M, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Absci's net income of -$26.3M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Absci's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci is 65.81x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ABSI
    Absci
    65.81x -- $1.2M -$26.3M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns ABSI or NNVC?

    Nanoviricides has a net margin of -2234.61% compared to Absci's net margin of --. Absci's return on equity of -51.63% beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ABSI
    Absci
    -- -$0.21 $202M
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About ABSI or NNVC?

    Absci has a consensus price target of $9.13, signalling upside risk potential of 235.48%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 280.12%. Given that Nanoviricides has higher upside potential than Absci, analysts believe Nanoviricides is more attractive than Absci.

    Company Buy Ratings Hold Ratings Sell Ratings
    ABSI
    Absci
    5 0 0
    NNVC
    Nanoviricides
    0 0 0
  • Is ABSI or NNVC More Risky?

    Absci has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.

  • Which is a Better Dividend Stock ABSI or NNVC?

    Absci has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ABSI or NNVC?

    Absci quarterly revenues are $1.2M, which are larger than Nanoviricides quarterly revenues of --. Absci's net income of -$26.3M is lower than Nanoviricides's net income of -$2.2M. Notably, Absci's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci is 65.81x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ABSI
    Absci
    65.81x -- $1.2M -$26.3M
    NNVC
    Nanoviricides
    -- -- -- -$2.2M
  • Which has Higher Returns ABSI or OGEN?

    Oragenics has a net margin of -2234.61% compared to Absci's net margin of --. Absci's return on equity of -51.63% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ABSI
    Absci
    -- -$0.21 $202M
    OGEN
    Oragenics
    -- -$0.12 --
  • What do Analysts Say About ABSI or OGEN?

    Absci has a consensus price target of $9.13, signalling upside risk potential of 235.48%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 420.83%. Given that Oragenics has higher upside potential than Absci, analysts believe Oragenics is more attractive than Absci.

    Company Buy Ratings Hold Ratings Sell Ratings
    ABSI
    Absci
    5 0 0
    OGEN
    Oragenics
    0 1 0
  • Is ABSI or OGEN More Risky?

    Absci has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

  • Which is a Better Dividend Stock ABSI or OGEN?

    Absci has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ABSI or OGEN?

    Absci quarterly revenues are $1.2M, which are larger than Oragenics quarterly revenues of --. Absci's net income of -$26.3M is lower than Oragenics's net income of -$2.2M. Notably, Absci's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci is 65.81x versus 1.84x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ABSI
    Absci
    65.81x -- $1.2M -$26.3M
    OGEN
    Oragenics
    1.84x -- -- -$2.2M
  • Which has Higher Returns ABSI or RXRX?

    Recursion Pharmaceuticals has a net margin of -2234.61% compared to Absci's net margin of -1366.49%. Absci's return on equity of -51.63% beat Recursion Pharmaceuticals's return on equity of -82.61%.

    Company Gross Margin Earnings Per Share Invested Capital
    ABSI
    Absci
    -- -$0.21 $202M
    RXRX
    Recursion Pharmaceuticals
    -47.31% -$0.50 $959M
  • What do Analysts Say About ABSI or RXRX?

    Absci has a consensus price target of $9.13, signalling upside risk potential of 235.48%. On the other hand Recursion Pharmaceuticals has an analysts' consensus of $7.43 which suggests that it could grow by 69.22%. Given that Absci has higher upside potential than Recursion Pharmaceuticals, analysts believe Absci is more attractive than Recursion Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ABSI
    Absci
    5 0 0
    RXRX
    Recursion Pharmaceuticals
    1 6 0
  • Is ABSI or RXRX More Risky?

    Absci has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Recursion Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock ABSI or RXRX?

    Absci has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci pays -- of its earnings as a dividend. Recursion Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ABSI or RXRX?

    Absci quarterly revenues are $1.2M, which are smaller than Recursion Pharmaceuticals quarterly revenues of $14.8M. Absci's net income of -$26.3M is higher than Recursion Pharmaceuticals's net income of -$202.5M. Notably, Absci's price-to-earnings ratio is -- while Recursion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci is 65.81x versus 23.19x for Recursion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ABSI
    Absci
    65.81x -- $1.2M -$26.3M
    RXRX
    Recursion Pharmaceuticals
    23.19x -- $14.8M -$202.5M
  • Which has Higher Returns ABSI or TOVX?

    Theriva Biologics has a net margin of -2234.61% compared to Absci's net margin of --. Absci's return on equity of -51.63% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ABSI
    Absci
    -- -$0.21 $202M
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About ABSI or TOVX?

    Absci has a consensus price target of $9.13, signalling upside risk potential of 235.48%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1527.91%. Given that Theriva Biologics has higher upside potential than Absci, analysts believe Theriva Biologics is more attractive than Absci.

    Company Buy Ratings Hold Ratings Sell Ratings
    ABSI
    Absci
    5 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is ABSI or TOVX More Risky?

    Absci has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

  • Which is a Better Dividend Stock ABSI or TOVX?

    Absci has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Absci pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ABSI or TOVX?

    Absci quarterly revenues are $1.2M, which are larger than Theriva Biologics quarterly revenues of --. Absci's net income of -$26.3M is lower than Theriva Biologics's net income of -$4.3M. Notably, Absci's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Absci is 65.81x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ABSI
    Absci
    65.81x -- $1.2M -$26.3M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Palo Alto Networks Stock Be in 5 Years?
Where Will Palo Alto Networks Stock Be in 5 Years?

You know those companies that just refuse to slow down…

UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?
UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?

Parcel delivery giant UPS (NYSE:UPS) has seen its fair share…

Where Will Coinbase Stock Be in 5 Years?
Where Will Coinbase Stock Be in 5 Years?

If you’ve been anywhere near the crypto world over the…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
84
SBET alert for May 28

SharpLink Gaming [SBET] is up 454.46% over the past day.

Buy
58
TNXP alert for May 28

Tonix Pharmaceuticals Holding [TNXP] is up 27.51% over the past day.

Sell
37
ATS alert for May 28

ATS [ATS] is up 19.57% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock